USA Today

2027 Kia Seltos Turbo AWD First Test: Premium, Plush, Problematic

A quick glance at the new 2027 Kia Seltos suggests a successful redesign—this second-generation model looks so much better than before. It mostly feels that way, too, delivering quality and refinement ...
Forbes

Test-Driving The 2027 Kia Telluride Turbo Hybrid

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The 2027 Kia Telluride Turbo Hybrid, specifically the X-Line SX-Prestige AWD, is a ...
Boating

Long-Term Test: Optima Orangetop Lithium Dual-Purpose Batteries

Last fall, I replaced the two AGM dual-purpose batteries aboard my Regulator center-console with Optima Orangetop lithium (LiFePO4) technology. I had used Optima AGM batteries for 15 years with ...
ConsumerAffairs

Kia Optima Extended Warranty: Cost, Coverage and Plans

Compare plans tailored to your car & budget. Getting an extended warranty for a Kia Optima — which was rebranded as the Kia K5 starting in 2021 — offers extra protection against unexpected repairs ...
The American Journal of Managed Care

OPTIMA: Prosigna Test Finds Which Patients With Breast Cancer Can Skip Chemotherapy

Prosigna testing identified roughly two-thirds of clinically high-risk patients who could omit adjuvant chemotherapy without meaningful detriment in 5-year invasive breast cancer–free survival.
TopSpeed

Kia Optima vs K5: Why the Discontinued Sedan May Be Smarter

Nathaniel is an experienced automotive writer with more than 10 years of automotive writing under his belt. From model reviews to industry politics to new innovations and development, he covers a wide ...
The American Journal of Managed Care

OPTIMA Finds Genomic Test Identifies Who Can Skip Breast Cancer Chemo: Iain MacPherson, PhD

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner. The OPTIMA trial represents a landmark advance in ...
Yahoo Finance

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node ...
AOL

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter ...
Business Wire

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment ...
ascopubs.org

First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early ...

Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer ...